A Phase Ib Study of Pembrolizumab in Bladder Cancer

Clinical Pearls

Elizabeth Plimack, MD, MS, director, Genitourinary Clinical Research, Fox Chase Cancer Center, discusses a phase Ib study of pembrolizumab for the treatment of patients with bladder cancer.

• 33 patients with urothelial tract cancer were enrolled on this trial.
• A subset of patients experienced a decrease in tumor volume. There were 3 complete responses.
• Overall survival data seen in this study were at the top bound of historical data.

<<<

View more from the 2014 ESMO Congress